



eRx DELIVERS 99% OF
eSCRIPTS IN UNDER
3 SECONDS.

90% in under 1 second.

eRx
script exchange

Today's issue of PD

Pharmacy Daily today has
two pages of news plus the
latest MIMS update.

No botanical slimming

THE Therapeutic Goods
Administration (TGA)
has issued a Safety
Advisory for
a product
labelled
Solve
Botanical Slimming.

The TGA
warns that the
capsules contain
the undeclared
substances diuretic furosemide
(frusemide), phenolphthalein and
paracetamol.

Furosemide and phenolphthalein
are prescription-only medicines,
and the products have not been
assessed by the TGA for quality,
safety or efficacy.

Consumers are advised to return
any remaining capsules to their
local pharmacy for safe disposal.



New Priceline Perdís pact

PRICELINE Pharmacy
has launched a new
partnership with
cosmetics brand
Napoleon Perdís, as
part of a significant
range expansion
to meet changing
customer demands.

The agreement was
announced yesterday
at the Priceline
Pharmacy annual
conference, where gm
Tamalin Morton said
evolving shopping habits meant the
company would further accentuate
its highly popular mass market
brands with more "exclusive and
cult product options".

The new Napoleon Perdís
products will include existing items
along with additional products
developed exclusively for Priceline.

"The exclusive Napoleon
Perdís products will provide our
customers with access to unique
makeup artistry that they can't find



anywhere else which
includes blush and
eye palettes, skincare,
primers, supercharged
serums, masks and
concealers," Morton
said.

More than 500
delegates are
attending the
Priceline Pharmacy
conference in Perth,
and were thrilled at
a presentation from
the creator himself,

Napoleon Perdís (**pictured**), who
said the pact was "a wonderful
opportunity...to provide so many
more customers with choice and
empowerment to achieve their
individually desired look and feel".

The Napoleon Perdís range
will begin rolling out across the
Priceline Pharmacy network in Aug
this year, with the group saying
it would help cement its position
as "Australia's favourite beauty
playground".

Breastfeeding protects against obesity

NEW longitudinal
research out of the
Children's Hospital
Research Institute of
Manitoba, Canada,
has demonstrated that
breastfeeding may
be protective against
obesity, and gut microbiota may
contribute to this effect.

Published in *JAMA Pediatrics*,
the study involved 1,087 infants
(507 girls and 580 boys), with
approximately half exclusively
breastfed for three months and
half exclusively fed formula for the
same period.

Authors concluded that formula
feeding appeared to stimulate
changes in microbiota associated
with excess weight, whereas other
complementary foods did not.

They explained that subtle
microbiota differences emerged
after brief exposure to formula in
the hospital.

The formula used in the study
was not identified - [CLICK HERE](#).



Formulated by science

for your pharmacy



**PRACTITIONER
STRENGTH**

AMPLIO+
FORMULATED BY SCIENCE

Speak to your Apotex Territory Manager for more information

Stay up to date
on the go

Download the app



Tipping winners

CONGRATULATIONS to Mark Low from Fred IT Group who was the top tipper in round 13 of the **Pharmacy Daily** NRL footy tipping competition this week.

The round 11 AFL tipping winner was Michael Japp from TerryWhite Chemmart Bennett Springs.



Dispensary Corner

WE ALL know avocados are a superfood, but this is probably taking things a little too far.

A man in Chile this week purchased a brand new mobile phone using several bags of the hipster-friendly savoury fruit.

In Chile there's currently a major shortage of avocados, with prices rocketing to more than 5,000 pesos (US\$8) per kilogram in street markets.

Supermarket group Ripley has leveraged the strong interest in the issue by displaying the "equivalent price in avocados" for some sale items - including a tongue-in-cheek sale of a Motorola smartphone which was listed as either 189,990 pesos or 58kg of the superfood.

A social media personality known as "El Weon de las Paltas" (The Avocado Guy) found the offer too enticing to pass up, arriving at the store with the required avocado supplies which he successfully used to purchase the new X4 smartphone (**below**).



Pharmacist refused rego

THE NSW Civil and Administrative Tribunal has declined to allow the reinstatement of the registration of former pharmacist Dale Larden, who had his registration cancelled by the Pharmacy Tribunal in 2009.

Larden was seeking a review of the cancellation order which was issued following complaints he was guilty of professional misconduct, had been convicted of various criminal offences relating to drugs of addiction, and that he was himself addicted to oxycodone and/or methadone.

In a statement tendered to the hearing Larden said he had managed to turn his life around since these incidents, and had not taken any opioid derived medication since late 2012.

He is now contemplating a return to pharmacy, possibly working in the country where he has purchased a property.

After extensive cross-examination and consideration of other statements, the Tribunal decided the application for reinstatement was "premature," taking into account a lack of concrete plan by Larden to return to pharmacy and a perceived lack of insight into the causes of his addiction.

The decision suggested he could consider continuing professional development, mentoring, joining a professional pharmacy organisation and undergoing regular drug tests, and demonstrate these matters to the Tribunal after a period of at least 12 months.

Details at caselaw.nsw.gov.au.

New diabetes app

ABBOTT has announced that its FreeStyle LibreLink app is now available for use with both iPhone and Android smartphones.

People using the FreeStyleLibre system are now able to access glucose data directly from their devices, eliminating the need to carry a separate device to scan.

The system was first released in Australia last year (**PD** 02 Nov 17).

Win with Nutri-Synergy

Every day this week **Pharmacy Daily** and Plunkett's are giving away an NS prize pack valued at over \$30.

Nutri-Synergy (NS) combines natural active ingredients to treat dry, sensitive and problem skin. NS works with the skin, not just on the skin's surface. Use NS Sensitive Skin Cleanser to clean and hydrate your skin before applying NS-21 Skin Repair Treatment to restore problem or damaged skin to a healthy state. Visit: www.NutriSynergy.com.au.

To win, be the first from QLD to send the correct answer to the question to comp@pharmacydaily.com.au



Nutri-Synergy is Natural Dermatology. Name two benefits of Natural Skincare.

Congratulations to yesterday's winner, Marina Atanasovska from Chemsave.



Guild Update

The health record revolution is coming

MORE than 40 per cent of community pharmacies are now registered with the My Health Record system.

The number of connections a week has increased over recent months, and the Guild is committed to helping build the digital health capabilities of community pharmacies and advance the efficiency, quality, and delivery of healthcare for all Australians.

The Guild is working with the Australian Digital Health Agency to ensure that community pharmacy dispensing and medicine-related services are fully integrated into the My Health Record.

My Health Record enables important health information including allergies, medical conditions, treatments, medicines, and test reports to be securely shared between clinicians and their patients. It also allows people to take more control of their own health and wellbeing, manage their children's health, and upload key documents like advanced care directives.

The My Health Record [website](http://www.mhrecord.gov.au) has been redesigned and updated and includes a [community pharmacy](http://www.mhrecord.gov.au) section.

New Products

- **Avelumab (rch) (Bavencio)** is a fully human IgG1 monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab removes the suppressive effects of PD-L1 on cytotoxic CD8⁺ T-cells, resulting in the restoration of anti-tumour T-cell responses. Bavencio is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma. This indication is approved based on tumour response rate, duration of response in a single arm study. Bavencio concentrated solution for intravenous infusion (200 mg/10 mL) is available in a pack size of 1 vial.
- **Cladribine (Mavenclad)** is a nucleoside analogue of deoxyadenosine. The mechanism by which cladribine exerts its therapeutic effects in multiple sclerosis (MS) is not fully elucidated but its predominant effect on B and T lymphocytes is thought to interrupt the cascade of immune events central to MS. Mavenclad is indicated for the treatment of relapsing-remitting MS to reduce the frequency of clinical relapses and to delay the progression of physical disability. Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. Re-initiation of therapy after year 4 has not been studied. Mavenclad is contraindicated with: human immunodeficiency virus infection; active chronic infections (tuberculosis, hepatitis); immunocompromise, including patients receiving immunosuppressive or myelosuppressive therapy with agents such as ciclosporin, methotrexate, mitoxantrone, azathioprine, natalizumab, or chronic use of corticosteroids (acute short-term therapy with corticosteroids can be administered); moderate or severe renal impairment (creatinine clearance < 60 mL/min); pregnancy and breastfeeding. Mavenclad 10 mg tablets are available in a pack size of 1, 4 and 6.
- **Dulaglutide (rch) (Trulicity)** is an engineered long-acting GLP-1 receptor agonist, with a GLP-1 analogue sequence covalently linked to a modified human IgG4 heavy chain fragment (Fc). Trulicity is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: as monotherapy; in combination with the oral glucose lowering medications metformin, metformin and sulfonylurea, metformin and thiazolidinedione; in combination with prandial insulin, with or without metformin. Trulicity solution for injection (1.5 mg/0.5 mL) is available as a single dose, ready to use prefilled pen (autoinjector) in a pack size of 4.
- **Fluticasone furoate/umeclidinium (bromide)/vilanterol (trifenatate) (Trelegy Ellipta)** represent three classes of medications: a synthetic corticosteroid (an inhaled corticosteroid (ICS)), a long-acting muscarinic receptor antagonist (LAMA), and a selective, long-acting β_2 -receptor agonist (LABA), respectively. Trelegy Ellipta is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with LAMA + LABA + ICS. Trelegy Ellipta is not indicated for the initiation of therapy in COPD. Trelegy Ellipta is contraindicated in patients with severe milk protein allergy. Trelegy Ellipta is available as a moulded plastic device containing two foil blister strips (each foil strip contains 30 regularly distributed blisters), with one strip containing fluticasone furoate 100 microgram and the other strip containing umeclidinium (bromide) 62.5 microgram and vilanterol (trifenatate) 25 microgram.
- **Pegaspargase (Oncaspar)** is a modified (pegylated) version of the enzyme asparaginase, which cleaves the amino acid asparagine into aspartic acid and ammonia. Depletion of asparagine in blood serum results in inhibition of protein synthesis, especially in leukaemic blasts which are not able to synthesise asparagine, thus undergoing cell death. Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia. Oncaspar is contraindicated with a history of: serious thrombosis during previous asparaginase therapy; pancreatitis including pancreatitis related to previous asparaginase therapy; serious haemorrhagic events during previous asparaginase therapy; severe hepatic impairment. Oncaspar solution for injection (3750 units/5 mL) is available in a pack size of 1.

*This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.*